Risk of Post-SSRI Sexual Dysfunction: A Retrospective Study
A recent retrospective cohort study has shed light on the small but significant risk of Post-SSRI Sexual Dysfunction (PSSD) in males treated with serotonergic antidepressants (SAs). Conducted over 19 years, the study involved 12,302 males and aimed to assess the likelihood of developing erectile dysfunction (ED) and PSSD following SA treatment.
The results show that males treated with SAs have a more than threefold increased risk of ED, with 0.46% developing PSSD. This finding highlights the need for open communication about the potential long-term sexual side effects of antidepressants.
While PSSD is rare, its implications are serious, making it crucial for healthcare providers to discuss these risks with patients before prescribing serotonergic antidepressants.
Read the full study here.
Learn more about PFS & PSSD
What is Post-Finasteride Syndrome?
PFS (Post-Finasteride Syndrome) is a complex and life-altering condition caused by the drug Finasteride (also marketed as Propecia) and other 5ar inhibitors. It affects physical, mental, and sexual health, leaving patients to suffer without adequate support, recognition or treatment.
What is Post-SSRI Sexual Dysfunction?
PSSD (Post-SSRI Sexual Dysfunction) is a serious and debilitating condition associated with the use of selective serotonin reuptake inhibitors (SSRIs) and similar drugs. It affects mental, physical, and sexual well-being, leaving many patients to suffer without sufficient support, recognition, or effective treatment.
